Additionally, it has been discovered that exogenous eNAMPT increases the proliferation of breast cancer cells by causing the activation of AKT and ERK1/2, which can be treated with AKT and ERK1/2 inhibitors (Gholinejad et al., 2017). Here, MAPK3 is linked to breast cancer.